Cargando…

Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season

INTRODUCTION: Influenza immunisation is recommended for elderly people each season. The influenza vaccine effectiveness (IVE) varies annually due to influenza viruses evolving and the vaccine composition. AIM: To estimate, in inpatients ≥ 60 years old, the 2017/18 trivalent IVE, overall, by vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Mira-Iglesias, Ainara, López-Labrador, F Xavier, Baselga-Moreno, Víctor, Tortajada-Girbés, Miguel, Mollar-Maseres, Juan, Carballido-Fernández, Mario, Schwarz-Chavarri, Germán, Puig-Barberà, Joan, Díez-Domingo, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685101/
https://www.ncbi.nlm.nih.gov/pubmed/31387672
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.31.1800461
_version_ 1783442340133732352
author Mira-Iglesias, Ainara
López-Labrador, F Xavier
Baselga-Moreno, Víctor
Tortajada-Girbés, Miguel
Mollar-Maseres, Juan
Carballido-Fernández, Mario
Schwarz-Chavarri, Germán
Puig-Barberà, Joan
Díez-Domingo, Javier
author_facet Mira-Iglesias, Ainara
López-Labrador, F Xavier
Baselga-Moreno, Víctor
Tortajada-Girbés, Miguel
Mollar-Maseres, Juan
Carballido-Fernández, Mario
Schwarz-Chavarri, Germán
Puig-Barberà, Joan
Díez-Domingo, Javier
author_sort Mira-Iglesias, Ainara
collection PubMed
description INTRODUCTION: Influenza immunisation is recommended for elderly people each season. The influenza vaccine effectiveness (IVE) varies annually due to influenza viruses evolving and the vaccine composition. AIM: To estimate, in inpatients ≥ 60 years old, the 2017/18 trivalent IVE, overall, by vaccine type and by strain. The impact of vaccination in any of the two previous seasons (2016/17 and 2015/16) on current (2017/18) IVE was also explored. METHODS: This was a multicentre prospective observational study within the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI, Spain). The test-negative design was applied taking laboratory-confirmed influenza as outcome and vaccination status as main exposure. Information about potential confounders was obtained from clinical registries and/or by interviewing patients; vaccine information was only ascertained by registries. RESULTS: Overall, 2017/18 IVE was 9.9% (95% CI: −15.5 to 29.6%), and specifically, 48.3% (95% CI: 13.5% to 69.1%), −29.9% (95% CI: −79.1% to 5.8%) and 25.7% (95% CI: −8.8% to 49.3%) against A(H1N1)pdm09, A(H3N2) and B/Yamagata lineage, respectively. For the adjuvanted and non-adjuvanted vaccines, overall IVE was 10.0% (95% CI: −24.4% to 34.9%) and 7.8% (95% CI: −23.1% to 31.0%) respectively. Prior vaccination significantly protected against influenza B/Yamagata lineage (IVE: 50.2%; 95% CI: 2.3% to 74.6%) in patients not vaccinated in the current season. For those repeatedly vaccinated against influenza A(H1N1)pdm09, IVE was 46.4% (95% CI: 6.8% to 69.2%). CONCLUSION: Our data revealed low vaccine effectiveness against influenza in hospitalised patients ≥60 years old in 2017/18. Prior vaccination protected against influenza A(H1N1)pdm09 and B/Yamagata-lineage.
format Online
Article
Text
id pubmed-6685101
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-66851012019-08-26 Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season Mira-Iglesias, Ainara López-Labrador, F Xavier Baselga-Moreno, Víctor Tortajada-Girbés, Miguel Mollar-Maseres, Juan Carballido-Fernández, Mario Schwarz-Chavarri, Germán Puig-Barberà, Joan Díez-Domingo, Javier Euro Surveill Research INTRODUCTION: Influenza immunisation is recommended for elderly people each season. The influenza vaccine effectiveness (IVE) varies annually due to influenza viruses evolving and the vaccine composition. AIM: To estimate, in inpatients ≥ 60 years old, the 2017/18 trivalent IVE, overall, by vaccine type and by strain. The impact of vaccination in any of the two previous seasons (2016/17 and 2015/16) on current (2017/18) IVE was also explored. METHODS: This was a multicentre prospective observational study within the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI, Spain). The test-negative design was applied taking laboratory-confirmed influenza as outcome and vaccination status as main exposure. Information about potential confounders was obtained from clinical registries and/or by interviewing patients; vaccine information was only ascertained by registries. RESULTS: Overall, 2017/18 IVE was 9.9% (95% CI: −15.5 to 29.6%), and specifically, 48.3% (95% CI: 13.5% to 69.1%), −29.9% (95% CI: −79.1% to 5.8%) and 25.7% (95% CI: −8.8% to 49.3%) against A(H1N1)pdm09, A(H3N2) and B/Yamagata lineage, respectively. For the adjuvanted and non-adjuvanted vaccines, overall IVE was 10.0% (95% CI: −24.4% to 34.9%) and 7.8% (95% CI: −23.1% to 31.0%) respectively. Prior vaccination significantly protected against influenza B/Yamagata lineage (IVE: 50.2%; 95% CI: 2.3% to 74.6%) in patients not vaccinated in the current season. For those repeatedly vaccinated against influenza A(H1N1)pdm09, IVE was 46.4% (95% CI: 6.8% to 69.2%). CONCLUSION: Our data revealed low vaccine effectiveness against influenza in hospitalised patients ≥60 years old in 2017/18. Prior vaccination protected against influenza A(H1N1)pdm09 and B/Yamagata-lineage. European Centre for Disease Prevention and Control (ECDC) 2019-08-01 /pmc/articles/PMC6685101/ /pubmed/31387672 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.31.1800461 Text en This article is copyright of the authors or their affiliated institutions, 2019. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research
Mira-Iglesias, Ainara
López-Labrador, F Xavier
Baselga-Moreno, Víctor
Tortajada-Girbés, Miguel
Mollar-Maseres, Juan
Carballido-Fernández, Mario
Schwarz-Chavarri, Germán
Puig-Barberà, Joan
Díez-Domingo, Javier
Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season
title Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season
title_full Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season
title_fullStr Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season
title_full_unstemmed Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season
title_short Influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, Valencia Region, Spain, 2017/18 influenza season
title_sort influenza vaccine effectiveness against laboratory-confirmed influenza in hospitalised adults aged 60 years or older, valencia region, spain, 2017/18 influenza season
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685101/
https://www.ncbi.nlm.nih.gov/pubmed/31387672
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.31.1800461
work_keys_str_mv AT miraiglesiasainara influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT lopezlabradorfxavier influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT baselgamorenovictor influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT tortajadagirbesmiguel influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT mollarmaseresjuan influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT carballidofernandezmario influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT schwarzchavarrigerman influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT puigbarberajoan influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT diezdomingojavier influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason
AT influenzavaccineeffectivenessagainstlaboratoryconfirmedinfluenzainhospitalisedadultsaged60yearsoroldervalenciaregionspain201718influenzaseason